SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe rare diseases and cancer. The company's core values include dedication, integrity, and collaboration in their pursuit of discovering novel treatments. With a patient-centric approach, SpringWorks Therapeutics aims to improve the lives of individuals affected by these debilitating conditions. They prioritize scientific excellence and ethical practices to deliver safe and effective therapies. Through strategic partnerships and pioneering research, the company strives to bring hope and transformative solutions to patients in need. SpringWorks Therapeutics Inc is committed to making a lasting impact in the lives of patients and their families.

SpringWorks Therapeutics Inc is primarily present in the United States.

Some significant milestones achieved by SpringWorks Therapeutics Inc include the approval of their lead product candidate, Nirogacestat, for the treatment of desmoid tumors by the U.S. FDA. The company also received Fast Track and Orphan Drug designations for Nirogacestat, which further highlights its potential in addressing unmet medical needs. Additionally, SpringWorks Therapeutics Inc has successfully initiated multiple clinical trials evaluating various therapies for rare cancers and genetic diseases. These accomplishments demonstrate the company's commitment towards advancing innovative treatments and improving patients' lives.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing therapies for patients with severe rare diseases and cancer. Founded in 2017, SpringWorks Therapeutics is committed to delivering innovative treatments by leveraging its strategic collaborations and advanced drug development expertise. With a diverse pipeline of investigational therapies, the company aims to address unmet medical needs and improve patients' lives globally. SpringWorks Therapeutics Inc has made significant progress in its mission to transform the lives of patients through its dedication to scientific excellence and groundbreaking research in the field of precision medicine.

The main competitors of SpringWorks Therapeutics Inc in the market include companies like Novartis, Pfizer, and Roche.

SpringWorks Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of SpringWorks Therapeutics Inc. is focused on developing and commercializing innovative targeted therapies for patients with severe rare diseases and cancer. The company aims to identify promising drug candidates and advance them through clinical development to address unmet medical needs. SpringWorks Therapeutics Inc. collaborates with both academic institutions and industry partners to leverage its expertise and optimize the development of potential treatments. By utilizing targeted therapies, the company aims to provide effective and personalized solutions for patients, with a focus on improving their overall quality of life.

SpringWorks Therapeutics hissesinin F/K oranı -6,82.

SpringWorks Therapeutics KUV 17,08 dir.

SpringWorks Therapeutics için AlleAktien Kalite Skoru 3/10'dur.

beklenen SpringWorks Therapeutics cirosu 139,41 Milyon. USD dir.

beklenen SpringWorks Therapeutics karı -349,27 Milyon. USD olarak gerçekleşmiştir.

SpringWorks Therapeutics is a biopharmaceutical company focused on developing therapeutics for patients with rare severe diseases. The business model involves developing innovative therapies with high medical necessity and making them accessible to the market. The company specializes in three main areas: oncology, inherited metabolic disorders, and neurological disorders. SpringWorks aims to develop new and effective therapies for each of these diseases. In the oncology sector, SpringWorks utilizes its expertise in drug discovery and development to create innovative cancer therapies. One of the leading products is Nirogacestat, a Notch pathway inhibitor that has the potential to be used against solid tumors that do not respond to other forms of therapy. In the inherited metabolic disorders division, SpringWorks is working on developing therapies for patients with rare diseases such as Niemann-Pick Type C syndrome. The company has partnered with Cydan Development, a company specializing in developing drugs for rare genetic disorders, for this purpose. In the field of neurological disorders, SpringWorks aims to develop therapies for patients with rare genetic diseases such as epilepsy and Huntington's disease. The company has initiated a collaboration with the Hospital for Sick Children in Toronto for this purpose. The company also has an innovative technology called "Biomarker Relocation" which allows for the identification of patients with certain rare diseases that are otherwise difficult to diagnose and treat. The technology is currently a significant component of SpringWorks' research and development efforts. In recent years, the company has raised capital through investments and collaborations for its business model. The funding has been based on venture capital from leading companies including Novartis Venture Fund, Pfizer Ventures, and OrbiMed. SpringWorks' business strategy also includes partnerships with other companies and research institutions. One collaboration, for example, exists with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research. The vision of SpringWorks is to play a leading role in the development of therapeutics for patients with rare diseases and to meet the medical need in this area. The company strives to improve the lives of patients with rare diseases and provide them with an optimal medication that alleviates their condition and enhances their quality of life. Overall, SpringWorks is an emerging player in the biotech industry, developing innovative therapeutics to address the needs of patients with rare diseases. With a presence in multiple medical specialties and a strong financing base, the company is poised to secure a position at the forefront of the biotech industry.

SpringWorks Therapeutics, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

SpringWorks Therapeutics için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

SpringWorks Therapeutics şirketinin ISIN kodu US85205L1070’dir.

SpringWorks Therapeutics 'nin WKN'si A2PRLN 'dir.

SpringWorks Therapeutics için Ticker SWTX’dir.

Son 12 ay içerisinde SpringWorks Therapeutics, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için SpringWorks Therapeutics, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

SpringWorks Therapeutics şirketinin mevcut temettü verimi .

SpringWorks Therapeutics dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

SpringWorks Therapeutics, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

SpringWorks Therapeutics, 'Sağlık' sektörüne atanmıştır.

Son SpringWorks Therapeutics tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 24.07.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 24.07.2024 olarak gerçekleşti.

2023 yılında SpringWorks Therapeutics tarafından 0 USD olarak temettüler dağıtıldı.

SpringWorks Therapeutics hisselerinin temettüleri USD olarak dağıtılır.